Abstract
The adenosine A2A receptor (A2AR) is in the center of a neuromodulatory network affecting a wide range of neuropsychiatric functions by interacting with and integrating several neurotransmitter systems, especially dopaminergic and glutamatergic neurotransmission. These interactions and integrations occur at multiple levels, including (1) direct receptor- receptor cross-talk at the cell membrane, (2) intracellular second messenger systems, (3) trans-synaptic actions via striatal collaterals or interneurons in the striatum, (4) and interactions at the network level of the basal ganglia. Consequently, A2ARs constitute a novel target to modulate various psychiatric conditions. In the present review we will first summarize the molecular interaction of adenosine receptors with other neurotransmitter systems and then discuss the potential applications of A2AR agonists and antagonists in physiological and pathophysiological conditions, such as psychostimulant action, drug addiction, anxiety, depression, schizophrenia and learning and memory.
Keywords: Adenosine, A2A receptor, caffeine, psychostimulant, amphetamine, cocaine, schizophrenia, anxiety, depression, dopamine
Current Neuropharmacology
Title: Adenosine A2A Receptors in Psychopharmacology: Modulators of Behavior, Mood and Cognition
Volume: 7 Issue: 3
Author(s): Hai-Ying Shen and Jiang-Fan Chen
Affiliation:
Keywords: Adenosine, A2A receptor, caffeine, psychostimulant, amphetamine, cocaine, schizophrenia, anxiety, depression, dopamine
Abstract: The adenosine A2A receptor (A2AR) is in the center of a neuromodulatory network affecting a wide range of neuropsychiatric functions by interacting with and integrating several neurotransmitter systems, especially dopaminergic and glutamatergic neurotransmission. These interactions and integrations occur at multiple levels, including (1) direct receptor- receptor cross-talk at the cell membrane, (2) intracellular second messenger systems, (3) trans-synaptic actions via striatal collaterals or interneurons in the striatum, (4) and interactions at the network level of the basal ganglia. Consequently, A2ARs constitute a novel target to modulate various psychiatric conditions. In the present review we will first summarize the molecular interaction of adenosine receptors with other neurotransmitter systems and then discuss the potential applications of A2AR agonists and antagonists in physiological and pathophysiological conditions, such as psychostimulant action, drug addiction, anxiety, depression, schizophrenia and learning and memory.
Export Options
About this article
Cite this article as:
Shen Hai-Ying and Chen Jiang-Fan, Adenosine A2A Receptors in Psychopharmacology: Modulators of Behavior, Mood and Cognition, Current Neuropharmacology 2009; 7 (3) . https://dx.doi.org/10.2174/157015909789152191
DOI https://dx.doi.org/10.2174/157015909789152191 |
Print ISSN 1570-159X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6190 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Preface
Current Pharmaceutical Design Basic Pharmacology of NMDA Receptors
Current Pharmaceutical Design Immune Responses to Adeno-Associated Virus Vectors
Current Gene Therapy Lifelong Endocrine Fluctuations and Related Cognitive Disorders
Current Pharmaceutical Design Screening of Some Novel 4, 5 Disubstituted 1, 2, 4-Triazole-3-thiones for Anticonvulsant Activity
Central Nervous System Agents in Medicinal Chemistry Beyond the Synapse and Hebb's Rule: Is the Rest of the Neuron More Important for Psychiatric Disorders?
Current Psychiatry Reviews NPY Signalling Pathway in Bone Homeostasis: Y1 Receptor as a Potential Drug Target
Current Drug Targets Neuroprotection for Ischemic Injury in the Immature Brain
Current Pediatric Reviews Maternal Choline Supplementation: A Potential Prenatal Treatment for Down Syndrome and Alzheimer’s Disease
Current Alzheimer Research The Biology of the RNA Binding Protein Guanine-Rich Sequence Binding Factor 1
Current Protein & Peptide Science Autism: Pathophysiology and Promising Herbal Remedies
Current Pharmaceutical Design PLGA Nanoparticles for Nose to Brain Delivery of Clonazepam: Formulation, Optimization by 32 Factorial Design, In Vitro and In Vivo Evaluation
Current Drug Delivery Other Drugs Acting on Nervous System Associated with QT-Interval Prolongation
Current Drug Safety Phentermine and Topiramate Extended-Release for the Obesity: New Kids on the Block
Recent Patents on Cardiovascular Drug Discovery Needle in a Haystack: Targeting Specific Glucuronidases Amid the Human Microbiome
Current Enzyme Inhibition Effect of Dietary Supplementation of Black Seed (N. Sativa L.) on Lipid Profile of Patients Suffering from Diabetes
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Effect of the NMDA-Receptor Antagonist Dextromethorphan in Infant Rat Pneumococcal Meningitis
Current Drug Metabolism Electrochemical Sensors in the Development of Selective Methods for Antiepileptic Drugs Determination
Combinatorial Chemistry & High Throughput Screening Astrocytic Target Mechanisms in Epilepsy
Current Medicinal Chemistry The Urokinase Receptor in the Central Nervous System
CNS & Neurological Disorders - Drug Targets